CoChat

A kinase-independent function of AKT promotes cancer cell survival

Open access
Vivanco, Igor, Chen, Zhi C, Tanos, Barbara, Oldrini, Barbara, Hsieh, Wan-Ying, Yannuzzi, Nicolas, Campos, Carl, Mellinghoff, Ingo K · 2014 · eLife
Cited by 87

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

The serine–threonine kinase AKT regulates proliferation and survival by phosphorylating a network of protein substrates. In this study, we describe a kinase-independent function of AKT. In cancer cells harboring gain-of-function alterations in MET, HER2, or Phosphatidyl-Inositol-3-Kinase (PI3K), catalytically inactive AKT (K179M) protected from drug induced cell death in a PH-domain dependent manner. An AKT kinase domain mutant found in human melanoma (G161V) lacked enzymatic activity in vitro and in AKT1/AKT2 double knockout cells, but promoted growth factor independent survival of primary human melanocytes. ATP-competitive AKT inhibitors failed to block the kinase-independent function of AKT, a liability that limits their effectiveness compared to allosteric AKT inhibitors. Our results broaden the current view of AKT function and have important implications for the development of AKT inhibitors for cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7554/elife.03751

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 21

  1. Arita, 1992, Growth of human melanocyte cultures supported by 12-O-tetradecanoylphorbol-13-acetate is mediated through protein kinase C activation, Cancer Research, 52, 4514
  2. Barretina, 2012, The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity, Nature, 483, 603, 10.1038/nature11003 · DOI · Paper page
  3. Calleja, 2009, Role of a novel PH-kinase domain interface in PKB/Akt regulation: structural mechanism for allosteric inhibition, PLOS Biology, 7, e17, 10.1371/journal.pbio.1000017 · DOI · Paper page
  4. Carpten, 2007, A transforming mutation in the pleckstrin homology domain of AKT1 in cancer, Nature, 448, 439, 10.1038/nature05933 · DOI · Paper page
  5. Chan, 2011, Resistance of Akt kinases to dephosphorylation through ATP-dependent conformational plasticity, Proceedings of the National Academy of Sciences of USA, 108, E1120, 10.1073/pnas.1109879108 · DOI
  6. Engelman, 2005, ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines, Proceedings of the National Academy of Sciences of USA, 102, 3788, 10.1073/pnas.0409773102 · DOI · Paper page
  7. Ericson, 2010, Genetic inactivation of AKT1, AKT2, and PDPK1 in human colorectal cancer cells clarifies their roles in tumor growth regulation, Proceedings of the National Academy of Sciences of USA, 107, 2598, 10.1073/pnas.0914018107 · DOI · Paper page
  8. Franke, 1995, The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase, Cell, 81, 727, 10.1016/0092-8674(95)90534-0 · DOI · Paper page
  9. Gherardi, 2012, Targeting MET in cancer: rationale and progress, Nature Reviews Cancer, 12, 89, 10.1038/nrc3205 · DOI · Paper page
  10. Green, 2008, Use of Akt inhibitor and a drug-resistant mutant validates a critical role for protein kinase B/Akt in the insulin-dependent regulation of glucose and system A amino acid uptake, The Journal of Biological Chemistry, 283, 27653, 10.1074/jbc.M802623200 · DOI
  11. Heerding, 2008, Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H- imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase, Journal of Medicinal Chemistry, 51, 5663, 10.1021/jm8004527 · DOI · Paper page
  12. Hirai, 2010, MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo, Molecular Cancer Therapeutics, 9, 1956, 10.1158/1535-7163.MCT-09-1012 · DOI · Paper page
  13. Landgraf, 2008, Molecular mechanism of an oncogenic mutation that alters membrane targeting: Glu17Lys modifies the PIP lipid specificity of the AKT1 PH domain, Biochemistry, 47, 12260, 10.1021/bi801683k · DOI · Paper page
  14. Lin, 2013, Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models, Clinical Cancer Research, 19, 1760, 10.1158/1078-0432.CCR-12-3072 · DOI · Paper page
  15. Okuzumi, 2009, Inhibitor hijacking of Akt activation, Nature Chemical Biology, 5, 484, 10.1038/nchembio.183 · DOI · Paper page
  16. Parikh, 2012, Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers, Proceedings of the National Academy of Sciences of USA, 109, 19368, 10.1073/pnas.1204384109 · DOI · Paper page
  17. Rhodes, 2008, Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity, Cancer Research, 68, 2366, 10.1158/0008-5472.CAN-07-5783 · DOI · Paper page
  18. She, 2008, Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling, PLOS ONE, 3, e3065, 10.1371/journal.pone.0003065 · DOI · Paper page
  19. Stephens, 1998, Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B, Science, 279, 710, 10.1126/science.279.5351.710 · DOI · Paper page
  20. Thomas, 2002, High-resolution structure of the pleckstrin homology domain of protein kinase b/akt bound to phosphatidylinositol (3,4,5)-trisphosphate, Current Biology, 12, 1256, 10.1016/S0960-9822(02)00972-7 · DOI · Paper page
  21. Wu, 2010, Crystal structure of human AKT1 with an allosteric inhibitor reveals a new mode of kinase inhibition, PLOS ONE, 5, e12913, 10.1371/journal.pone.0012913 · DOI · Paper page

Cited by

Metadata

Authors
Vivanco, I., Chen, Z. C., Tanos, B., Oldrini, B., Hsieh, W.-Y., Yannuzzi, N., Campos, C., & Mellinghoff, I. K.
Venue
eLife
Published
2014-12-31
Volume
3
ISSN
2050-084X (ISSN-L)
OpenAlex
W2129181865
Cited by
87
References
3
FWCI
2.43
Type
journal article
Language
en
Open access
gold
Funders
  • National Institutes of Health (1R01NS080944–01, U54CA143798, F32 GM096558)
  • James S. McDonnell Foundation
  • National Brain Tumor Society

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.